首页> 美国卫生研究院文献>CPT: Pharmacometrics Systems Pharmacology >Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?
【2h】

Quantitative Prediction of Drug–Drug Interactions Involving Inhibitory Metabolites in Drug Development: How Can Physiologically Based Pharmacokinetic Modeling Help?

机译:在药物开发中涉及抑制性代谢物的药物相互作用的定量预测:基于生理的药代动力学建模如何提供帮助?

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

This subteam under the Drug Metabolism Leadership Group (Innovation and Quality Consortium) investigated the quantitative role of circulating inhibitory metabolites in drug–drug interactions using physiologically based pharmacokinetic (PBPK) modeling. Three drugs with major circulating inhibitory metabolites (amiodarone, gemfibrozil, and sertraline) were systematically evaluated in addition to the literature review of recent examples. The application of PBPK modeling in drug interactions by inhibitory parent–metabolite pairs is described and guidance on strategic application is provided.
机译:该药物代谢领导小组(创新和质量联盟)下的这个子团队使用基于生理的药代动力学(PBPK)模型研究了循环抑制代谢产物在药物相互作用中的定量作用。除最近文献的文献综述外,还系统评估了三种具有主要循环抑制代谢物的药物(胺碘酮,吉非贝齐和舍曲林)。描述了PBPK模型在抑制性亲代代谢物对相互作用中的应用,并提供了战略应用指导。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号